retatrutide triple agonist gip glp-1 glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% retatrutide ly3437943 triple agonist glp-1
Pay in 4 interest-free payments of $5.75 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 14 - Nov 19




















![20 + 20 Gratis | ClipHold™ - Veilige bevestigingsclip voor schaduwdoeken [Laatste dag korting] schoenen](https://cdn.shopify.com/s/files/1/0911/6054/3575/files/Artboard14_1080x1080_dedc8e05-ca6b-4289-a171-db9104f12716.webp?v=1747478506)



